The funding will support the clinical validation and certification of Noxon’s non-invasive Muscle-Computer Interface and preparation for the market launch of its initial therapy modules.
Munich-based medtech company Noxon has closed its seed funding round, led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, with participation from Auxxo and another institutional investor. The size of the round was not disclosed.
In rehabilitation and the treatment of neuromuscular disorders, muscle diagnostics and activation are typically performed intermittently in clinical settings. As a result, patients often lack continuous data and adaptive therapy in their daily lives throughout the treatment process.
Noxon aims to address this gap with a medical Muscle-Computer Interface that combines continuous muscle diagnostics and neuromuscular electrical stimulation (NMES) in a wearable designed for everyday use.
The core innovation is a closed feedback loop that enables real-time measurement and personalised muscle and nerve activation throughout therapy, integrated into existing formats such as tapes, patches, and orthopaedic aids.
Noxon is also working with medical partners, including University Hospital Würzburg and the neuroscience group N-Squared Lab, on additional pilot applications. The collaboration focuses on supporting muscle control when signal transmission between the brain and muscle is impaired, including approaches aimed at reducing tremor in Parkinson’s patients.
With the new funding, Nexon will advance clinical validation of its platform and support the launch of its initial products, aiming to make muscle health more transparent, personalised, and accessible.